Navigation mit Access Keys

September 25, 2019

T3 Pharma: Lead product expected to enter clinical phase

The closing of the second financing round of over 12 million Swiss Francs and the strengthening of the development team pave the way for T3 Pharmaceuticals AG to enter the clinic. The company, a spin-off of the Biozentrum, University of Basel, is focusing on immuno-oncology therapies for the treatment of solid tumors.

T3 Pharma: Christoph Kasper (CSO), Claire Barton (CMO) and Simon Ittig (CEO).

“We are very pleased to be joined by two experienced and specialised investors, the Boehringer Ingelheim Venture Fund and Reference Capital SA. This is optimal for completing preclinical work, and for planning and conducting the clinical trials ahead of us,” comments Simon Ittig, CEO of T3 Pharmaceuticals (T3). “The support of these investors validates our work and indicates that we are on the right track. This strong setup allows us to keep focusing on our core business. Special thanks are due to our existing investors who have supported us since inception”. 

With the addition of these two new investors, the startup has now closed its second financing round with over 12 million Swiss Francs. To progress into the clinical phase, T3 appoints Claire Barton as Chief Medical Officer, strengthens its development team and announces the clinical advisory board.

Protein delivery technology to fight cancer

Collaboration with investors, a dedicated team and continued support from the Biozentrum of the University of Basel provide an excellent position for T3 to complete preclinical activities for its lead candidate, which originated from the T3 platform. 

T3 is developing a protein delivery technology based on live bacteria expressing the “type 3 secretion system”. The company has engineered the bacteria to grow selectively within solid tumors where they produce and deliver therapeutic proteins. T3’s lead product is expected to enter clinical testing in the middle of 2020.

About T3 Pharmaceuticals

T3 Pharmaceuticals was founded in May 2015 as a spin-off of the Biozentrum of the University of Basel, Switzerland. The Company is focusing on immuno-oncology (bacteria-based) therapies for the treatment of solid tumors. Cancer immunotherapy is seen as a turning point in the fight against cancer. Unlike traditional therapies that attack the tumor directly, the goal of immunotherapies is to stimulate the immune system to selectively recognize and attack tumor cells. 

T3 is among the first companies supported by BaseLaunch. It was awarded «Science Startup of the year 2018» at Falling Walls Venture, won the business plan competition in 2016 and recently the W.A. de Vigier Award. For further information, please visit

Contact: T3 Pharma, Simon Ittig